Biospecimens are critical to cancer research because they contain an extraordinary amount of biological information that can identify the biological characteristics of cancer cells at a specific point in time (1). Researchers can compare these biological patterns with the clinical picture of how different patients experience progression of their disease or how their disease responds to therapies. Critical to making progress in our fight against cancer is the availability of high-quality biospecimens (1). Biospecimen quality is dependent on standardized handling processes (2), and biospecimen research science that explores how collection, processing, storage, and transport procedures affect the biospecimen's molecular characteristics and ultimate usefulness in cancer research. The current biobanking system has a considerable shortage of high-quality, well-annotated biospecimens for cancer research (3,4). The impact of biospecimen quality and the effects on cancer research have been addressed in numerous publications (5-9).
Biospecimens are critical to cancer research because they contain an extraordinary amount of biological information that can identify the biological characteristics of cancer cells at a specific point in time (1). Researchers can compare these biological patterns with the clinical picture of how different patients experience progression of their disease or how their disease responds to therapies. Critical to making progress in our fight against cancer is the availability of high-quality biospecimens (1). Biospecimen quality is dependent on standardized handling processes (2) , and biospecimen research science that explores how collection, processing, storage, and transport procedures affect the biospecimen's molecular characteristics and ultimate usefulness in cancer research. The current biobanking system has a considerable shortage of high-quality, well-annotated biospecimens for cancer research (3, 4) . The impact of biospecimen quality and the effects on cancer research have been addressed in numerous publications (5) (6) (7) (8) (9) .
Because the repercussions of poor biospecimens have such a profound public health impact, the National Cancer Institute (NCI) is proposing a national solution through formation of the national cancer HUman Biobank (caHUB). NCI conducted extensive field research to determine whether a national resource would be supported and used by the cancer research community. The results of an initial survey conducted by NCI in October 2008 (10) concluded that researchers often questioned the validity of their research results and restricted the scope of their projects due to limited availability of fit-for-purpose biospecimens.
To supplement the survey findings, the NCI conducted qualitative research with decision makers who would have a direct influence on whether or not their organizations would participate in a caHUB. The input from these decision makers was deemed critical for informing the direction and success of a national resource. This article presents the findings from the qualitative research and discusses the decision makers' primary challenges around biospecimen collection and quality assurance, their perceived benefits and challenges for the development of the caHUB, barriers to its use, and critical steps that NCI must take to support its adoption by the field. The research was designed to address the following questions:
1. What are their organizations' primary challenges around biospecimen collection and quality assurance in the current environment? 2. What are the key benefits and challenges to their organizations in the development of a national caHUB? 3. What would prohibit their organizations from using a national caHUB?
determine support for a national caHUB. A qualitative, online interactive discussion approach was selected to gather perspectives from academic and pharmaceutical industry leaders who were considered potential primary users of caHUB. Before conducting the research, the study protocol and instruments were submitted to the National Institutes of Health, Office of Human Subjects Research for review and were designated "exempt" by the Office of Human Subjects Research.
Participants
Cancer program leaders at academic research institutions and executive-level decision makers from industry were identified as potential primary users of caHUB. A list of potential participants and contact information was compiled by the NCI Office of Biorepositories and Biospecimen Research staff and executive-level members of the pharmaceutical industry. The contractor sent invitations via e-mail, followed by phone calls when necessary, to individuals from the list. Each person was asked to participate in a facilitated interactive discussion with peers from other similar organizations around the country about their biospecimen needs and challenges and their reactions to caHUB. All respondents consented to participating in the study before their group's initiation.
Instrument
The research tool used for this study, Advanced Strategy Online (11), is a new online platform that allows participants to engage in collaborative activities (eg, brainstorming and voting) using their own computer (typing their responses) and to interact with their peers anonymously. During the sessions for this study, participants called in to a toll-free number where only the moderator was able to talk to the group (participant phones were muted during the session). The moderator would then orally pose an open-ended question that would also appear on each participant's screen (eg, "What do you see as the most significant challenges to the development of a caHUB?"). Participants were encouraged to brainstorm multiple responses by typing and submitting them anonymously for the group to see. For each open-ended question, a running list of all anonymous responses was generated for the participants to review. The platform then allowed the moderator to generate an abridged synthesized list of the responses in a table format (eg, if 45 responses were brainstormed, the moderator could collapse them into nine distilled themes). Each theme received its own row in the table, and participants were next asked to rate each row on a 10-point Likerttype scale (eg, low significance [1] to high significance [10] ). Upon submitting their ratings, participants could view the aggregate score and rankings for each theme. The moderator then picked the topranked theme from the list and asked participants to brainstorm and electronically submit ways to address them. This process was repeated for each of the research questions. Academic participants agreed to a 90-minute session, whereas industry participants were only able to commit to 60 minutes. The additional half hour for academic participants allowed the moderator to ask additional questions of this group, which are identified in the findings. All participants began the Advanced Strategy Online session by indicating the length of time they had been involved in biospecimen-related issues in their respective industry. Both groups responded to the following topics: benefits of a national standardized caHUB , challenges to developing a national standardized caHUB , challenges to obtaining the quality and quantity of biospecimens needed overall, and reasons why their organization might not use a national caHUB . The group representing industry further explored their concerns around intellectual property. The additional time with academic participants allowed them to prioritize operating procedures and practices that would need to be in place to have confidence in caHUB and identify ways to overcome barriers to the implementation of standard operating procedures and quality measures. For each area, individuals in each group first brainstormed responses and then were asked to rate each item in the summarized list, followed by a brainstorming around the highest ranked item on the summary list.
Methods
The Delphi method is designed as a group decision-making technique using a series of anonymous questionnaires to examine specific issues for the purpose of setting goals and policies and for predicting the occurrence of future events (12) . This method was deemed appropriate for this research because the objective was to determine buy-in and policies for a future resource with a group of experts in the field. Using an online Delphi method, we were able to convene decision makers from distributed locations and establish consensus on items of greatest importance. The Delphi method removes barriers to participation that are present in an in-person meeting where rank or dominance may prevent all from participating (12) . Thus, the Delphi method levels the playing field by allowing all participants to have an equal voice in the outcome.
To maintain homogeneity within the groups, two separate sessions were held. Participants in the first Advanced Strategy Online session were NCI grantees in academic research institutions who lead a cancer research program. Participants in the second Advanced Strategy Online session were pharmaceutical and biotechnology executive-level professionals in the area of oncology research and development.
Analysis
Findings are presented around each of the research questions posed above. Ideas generated in the brainstorming session for each openended question were analyzed categorically by grouping responses into themes. The themes and their mean scores, on a scale of 1-10, are presented according to their Advanced Strategy Online groups (academic institutions vs industry). In cases with longer lists, tables only present the top 10 rated items by group. For some questions, participants generated lists of fewer than 10 issues. This is noted in the table for these questions.
Results

Participants
Participants in the academic group (N = 13) predominantly held director, professor, or assistant professor positions, with the majority having more than 5 years experience in dealing with biospecimens and 36% having 10 or more years of experience. Participants in the industry group (N = 10) held executive director, vice president, or senior management positions in the area of oncology research and development with pharmaceutical or biotechnology companies. Fifty percent of industry participants had 5-10 years of experience, 30% had 10-20 years of experience, and 20% had 20 or more years of experience.
Challenges in Biospecimen Collection
Participants in each group were asked to identify and prioritize their current challenges in obtaining the necessary biospecimens needed for their organizations. Table 1 summarizes the key challenges presented by the two groups. The greatest challenge identified by both groups was sample quality with primary concerns around the inability to link treatment history to samples, sample preservation methods, and the general lack of training around complex biospecimen-handling procedures. As noted by an industry participant, "Resources (people, time) can be wasted on the analysis of poor quality specimens or worse still, spurious results could be obtained if the poor quality is not recognized." Additionally, obtaining access to samples from biased populations and rare specimens were cited by both groups as important challenges that need to be addressed.
Institutional review boards are responsible for approving the process and language used to obtain patient consent for the use of their samples in research. Participants from both groups in this study indicated that the complexity of the internal institutional review board process was a hindrance, with academic participants noting that institutional review board approvals are too intensive and time consuming and industry participants highlighting closedended limited consent as a major roadblock.
Academic participants in this study highly ranked the importance of the clinician in resolving the biospecimen quality issue as a major challenge, citing lack of participation and expertise on the part of the clinician in biospecimen preservation. Similarly, the annotation of clinical data was also perceived as a major challenge, with both academic and industry participants citing lack of clinical data and the inability to link treatment history to the sample as a challenge.
Quality Concerns Around Biospecimens
Because sample quality was listed as the primary challenge in obtaining biospecimens in the current environment by both groups, the Advanced Strategy Online moderator brainstormed specific quality issues. Both academic institution and industry groups were asked to prioritize their greatest struggles around quality assurance in procuring biospecimens ( Table 2 ). The types of issues raised on this topic for each group were thematically similar and produced a list of only eight top issues for academic institution participants and six for industry participants. Time to fixation of tumor samples (ie, the length of time between removal of the biospecimen during surgery and the point that it is preserved or fixed) was recognized as a primary quality assurance factor by both groups. The development of standard operating procedures by a centralized resource was viewed as beneficial and having a positive effect on many of the challenges specified by both groups such as inconsistent patient-consenting, processing, and handling procedures. As noted by an academic institution participant, "Currently inconsistent results hamper progress, create a lot of duplication, at great expense." Ensuring reporting on compliance of standard operating procedures was also cited as a major concern.
Benefits of the Development of a National caHUB
The Advanced Strategy Online sessions sought to identify the perceived benefits to stakeholders of the development of caHUB and which were of highest priority (Table 3) . Overwhelmingly, participants from both groups indicated a clear and universal need for standards around biospecimens collection and storage for which they believe a national resource could provide a solution. In fact, standardization was the predominant theme among both groups' prioritization of benefits. One industry participant wrote: "Standardized collection procedures ensure that data obtained using the specimens can be trusted. That is, it minimizes the pre-analytic variability when interrogating data derived from these specimens." Academic participants perceived that the greatest benefit of caHUB would be its ability to help standardize studies between laboratories, which would improve their ability to correlate clinical outcome and develop strategies for individualized therapies. Industry participants ranked higher confidence in the quality of the biospecimen as the greatest benefit. Both groups perceived the centralization of standards as a means to increase confidence in biospecimen quality as critically important.
When asked to elaborate, members from both groups indicated that the top priorities could help increase reliability and consistency of research conclusions while conserving resources. For example, one academic participant submitted the following explanation:
"Improve access to quality samples; result would be improved quality of studies, faster studies, studies that might be poolable.
Both the research (academic) and development (industry) communities are currently hampered by access to samples."
Challenges in the Development of a National caHUB
Participants were asked to prioritize the biggest challenges in the development of a national caHUB (Table 4) . Although standardization was seen as the primary benefit for the establishment of a caHUB and critical for its success, it was also seen as a significant challenge by participants in both groups. Though caHUB has the opportunity to define standard operating procedures for the biobanking industry, participants from both groups expressed concern over outlining the details of its infrastructure and quality control and defining its best practices. Specifically, participants were concerned about how such an infrastructure would be created and financially sustained. Participants from both groups also identified the challenge of getting investigators and organizations to participate in the caHUB, particularly those invested in a local resource.
Generating an adequate supply of tissue and establishing a fair means of determining allocation of biospecimens to researchers also ranked in the top 10.
One notable difference when asked about the challenges was the perceptions of intellectual property: how to deal with intellectual property issues was ranked extremely high for industry participants, whereas academic participants did not cite intellectual property as a top 10 issue for the development of caHUB.
Academic participants were further asked to prioritize operating procedures and practices that would need to be in place for them to have confidence in caHUB. Their ranked list is provided in Table 5 . The items that rose to the top of the list beyond the general need for standard operating procedures centered on the challenges of clearly differentiating tumor vs normal tissue and accurately recording ischemia time.
Academic participants made several recommendations on how barriers related to the implementation of standard operating procedures and quality control measures could be overcome: 
Barriers to Participation in caHUB
Both groups were asked to report on and prioritize their perceived barriers to participation in a caHUB. Although academic participants offered 10 clearly defined potential barriers, industry participants identified only five key issues (Table 6 ). Both groups agreed that a lack of clear understanding about the cost structure for such a resource could be a major barrier for participation. Academic respondents were particularly concerned with their institutions' lack of resources to support a national biobanking effort. Although they considered an immediate return on investment as a critical decision point, industry participants were more concerned over the potential for a lengthy investment period. Both groups also agreed that loss of control of the tissue could prevent organizations from participating. Where the two groups differed was in the ranking of intellectual property issues and competition for biospecimens. For industry, intellectual property constraints were considered the top barrier to participation in a centralized biospecimen resource, whereas it was not even listed as a top 10 barrier for participation by academic participants. Alternatively, academic participants ranked academic elitism and competition as a major barrier, but these barriers were not a concern cited by industry participants.
Policies for Overcoming Barriers
Both groups were asked to brainstorm potential solutions to overcome the perceived barriers to participation. The two groups differed in their views of how a national resource could deal with intellectual property issues. Academic participants specified that human tissue and biospecimens should be protected as experimental resources so that intellectual property would relate to research outcomes only (not the sample source). Industry participants took a much harder line on intellectual property ownership, suggesting it should not be tied to sample procurement; thus, the organization acquiring the biospecimen should own the rights to all products generated from the use of that biospecimen.
Another area where academic participants radically differed from industry participants was in the relationship to funding and caHUB participation. Academic participants suggested that caHUB participation should be required for National Institutes of Health funding, whereas industry participants indicated funding should not be tied to yearly budgets or annual grants.
Other potential solutions for overcoming barriers to participation proposed by participants include:
1. Long-term commitment with continuous funding (industry). 2. Increased funding (academic institutions). 3. Creation of tangible rewards for participation in caHUB including discounts, recognition, and reimbursement for shipping (academic institutions). 4. Keeping standard operating procedures minimal and concise (academic institutions).
Academic participants further indicated that the opportunity for collaboration, shared sense of mission, and NCI support and backing were motivators for participation in a national caHUB.
Discussion
The purpose of this study was to help the NCI develop a more detailed understanding of its findings from a quantitative survey on this topic conducted in October 2008 (10) . Findings from this qualitative research confirm that stakeholders of a national cancer human biobank unequivocally acknowledge the profound negative effect that poor or unknown quality biospecimens have on cancer research and the development of new cancer treatment strategies. With an estimated 300 million human biospecimens accrued for cancer research in 2000 and roughly 20 million biospecimens accruing annually (13) , the cost of getting biospecimen accrual wrong is significantly high both in terms of dollars and lack of progress in cancer research. Participants of this study uniformly expressed that biospecimens that are consistently processed and linked to clinical data are considered essential for progress in cancer research and developing the next generation of targeted therapies.
Setting consistent standards for biospecimen quality (academic institutions) and raising confidence in the quality of the biospecimens (industry) were identified as the two most important benefits (17) . As demand for biospecimens continues to increase, ensuring the integrity of the biospecimens that are available for these purposes will be even more important (18) . Clinicians play a vital role in preserving the molecular integrity of the biospecimen, a point highlighted by participants, with both academic and industry groups highly ranking participation and training of clinicians as an important factor in ensuring high-quality biospecimens and the success of caHUB. Not only are clinicians responsible for obtaining patient consent for the use of the patients' biospecimens in cancer research, they also provide the clinical data linked to the biospecimen, which will enable researchers to discern molecular changes that affect clinical characteristics such as survival outcome and response to therapy. Most importantly, the greatest impact on the molecular integrity of the biospecimen occurs in the operating room where surgical procedures and the length of time before biospecimens are fixed or preserved after removal can significantly alter the molecular characteristics of the biospecimen (19, 20) . Leveraging the recommendations of academic institution participants, NCI should consider the development of a working or advisory group that can provide expert guidance from surgeons, pathologists, and other operating room specialties to help develop operating room standard operating procedures. Additional focus-group research with these stakeholders is recommended to determine key barriers to participation and engage them in the solutions.
Agreement on the impact that poor quality biospecimens have on cancer research and the benefits of a centralized resource is demonstrated by the consistency of the issues raised by both groups. In almost all cases, the topics raised were frequently aligned between the two sessions, particularly on sample quality, standard operating procedures, institutional review board issues around patient consent, and clinical annotation of biospecimens. Based on NCI's experience with biospecimen collection for The Cancer Genome Atlas and the details garnered from this study, the solutions that a national centralized human biobank could provide are well recognized. With consensus on the primary issues by both groups of stakeholders, NCI should leverage this support and focus resources on overcoming potential barriers to participation identified by the two groups. Both academic and industry participants agreed that a stakeholder forum to provide guidance and oversight would be important.
Where the two groups differed was in what they believe poses the greatest barrier to participation in caHUB. Academic institution participants felt that funding and resources required for participation would be the greatest barrier, whereas industry participants felt that impositions on their organizations' intellectual property would be the biggest barrier. However, based on its ranking, the value that a centralized resource could bring to overcoming the biospecimen quality and standardization issues in the current environment was considered significant. Therefore, most stakeholders were generally optimistic that potential barriers could be overcome by clearly identifying the infrastructure, including costs, and agreeing on acceptable terms of intellectual property. It was clear from both groups that convening the community of stakeholders to provide feedback and guidance to the formation of caHUB was critically important. Several participants from both groups noted that the hosting of the Advanced Strategy Online sessions was an important first step in the process.
Qualitative research methods are not meant to provide results that can be generalized to a larger population of study participants. However, qualitative research facilitates a broader understanding and collaborating with key stakeholders fosters the stakeholders' trust and buy-in to the process by giving them a role in developing solutions, which have been shown to be effective in community-based participatory research (21, 22) . The strength of this qualitative research stems from the level of expertise and decision-making power of the participants as well as the opportunity to probe more deeply the results of the quantitative survey conducted by NCI on this topic. Support of, and further guidance from, these participants is crucial to ensure that caHUB is a valuable national resource that is used by a wide variety of stakeholders across the cancer research community.
Although there was a high level of consensus among the participants of each group with low standard deviations for each brainstorming session, and the findings were confirmatory of the earlier quantitative survey conducted by the NCI on this topic (10), additional Advanced Strategy Online sessions with academic and industry decision makers could provide further support, particularly in defining standard operating procedures, intellectual property constraints, and terms of access to the resource. The sample size of each Advanced Strategy Online session consisted of a small number of participants, partly because gaining access to industry decision makers at the senior management level was particularly challenging. Therefore, further Advanced Strategy Online sessions are recommended with additional stakeholders, such as industry regulators, to provide additional clarity on potential barriers and how these might be overcome to ensure participation in caHUB. Further research with operating room staff is also recommended to help define and implement operating room standard operating procedures, as noted earlier.
In summary, key stakeholders in a national human biobank support development of caHUB and acknowledge the benefits this institution could provide in creating standard operating procedures and access to a broad range and large number of qualitycontrolled biospecimens, with the greatest impact on improvements in cancer research results. Clear identification of caHUB infrastructure, interface, and costs will need to be determined before academic and industry representatives truly embrace this endeavor. Barriers to participation must then be addressed to increase use of such a system and, ultimately, the availability of quality biospecimen materials for science.
